Purple Biotech (PPBT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Purple Biotech (PPBT) has a cash flow conversion efficiency ratio of -0.108x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.04 Million) by net assets ($9.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PPBT days of operational coverage to measure how many days the company can operate on defensive assets alone.
Purple Biotech - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Purple Biotech's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Purple Biotech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Purple Biotech ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tivic Health Systems Inc
NASDAQ:TIVC
|
-0.453x |
|
Mobico Group Plc
LSE:MCG
|
-1.446x |
|
Duke Royalty Ltd
LSE:DUKE
|
0.039x |
|
NEVADA SUNRISE METALS
F:K4L
|
-0.750x |
|
Streamline Health Solutions Inc
NASDAQ:STRM
|
-0.088x |
|
Ordinary Fully Paid Deferred Settlement
AU:CDEDC
|
N/A |
|
Arbuthnot Banking Group Plc
LSE:ARBB
|
0.304x |
|
Berto Acquisition Corp. Warrant
NASDAQ:TACOW
|
0.000x |
Annual Cash Flow Conversion Efficiency for Purple Biotech (2013–2025)
The table below shows the annual cash flow conversion efficiency of Purple Biotech from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see PPBT market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.66 Million | $-5.54 Million | -0.573x | -31.31% |
| 2024-12-31 | $32.91 Million | $-14.37 Million | -0.437x | +24.86% |
| 2023-12-31 | $34.30 Million | $-19.93 Million | -0.581x | -63.50% |
| 2022-12-31 | $47.10 Million | $-16.73 Million | -0.355x | -53.50% |
| 2021-12-31 | $65.11 Million | $-15.07 Million | -0.231x | -52.67% |
| 2020-12-31 | $79.75 Million | $-12.09 Million | -0.152x | +70.49% |
| 2019-12-31 | $10.86 Million | $-5.58 Million | -0.514x | +33.32% |
| 2018-12-31 | $11.00 Million | $-8.48 Million | -0.771x | +23.24% |
| 2017-12-31 | $8.59 Million | $-8.63 Million | -1.004x | -114.60% |
| 2016-12-31 | $13.38 Million | $-6.26 Million | -0.468x | -33.35% |
| 2015-12-31 | $9.43 Million | $-3.31 Million | -0.351x | +94.01% |
| 2014-12-31 | $773.00K | $-4.53 Million | -5.855x | -1181.82% |
| 2013-12-31 | $-946.00K | $-512.00K | 0.541x | -- |
About Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, whi… Read more